Programs

Multivalent pneumococcal vaccine

We are developing a high-valent pneumococcal conjugate vaccine using Inventprise’s proprietary conjugation technology for pediatric populations globally. In addition, Inventprise is working on an adult formulation intended for use world wide.

The value of the pneumococcal vaccines market will steadily grow over from USD 7.2 billion (2019) to over USD 11 billion by 2030 representing the second largest segment of the vaccine industry (measured by dollar volume).. 

IVT-PCV-25 leverages our proprietary technology platform to provide the broadest coverage against pathogenic pneumococcal serotypes encountered by children. Each one of these serotypes has been carefully evaluated and determined to be critical for the protection of children under the age of 5 regardless of which country they live.

Currently in late stage preclinical development, IVT-PCV-25 will be indicated for immunization for the prevention of invasive pneumococcal disease and otitis media. Proof of concept clinical trials are expected to begin in 2022.

Heat-stable Rotavirus vaccine

We’ve developed an innovative low volume (0.5 mL or less) oral rotavirus vaccine formulation which does not require refrigeration, and therefore is more stable, easier to administer, and reduces cold storage, transport and distribution costs.

Market Rotavirus remains one of the deadliest threats to children and infants, especially in impoverished regions of the world. WHO estimates the disease kills about 215,000 children under 5 each year. Rotavirus vaccines produced by large multinational pharmaceutical companies need to be kept at 2°C to 8°C (36°F to 46°F) during storage and transportation. Another oral rotavirus vaccine produced by Bharat Biotech and launched in India during 2015, has to be kept frozen at -20°C (-4°F). 

The new vaccine utilizes our patented technology to produce a thermostable formulation. This improves the release of live attenuated rotavirus into the intestine to provide immunity.

Developing GMP manufacture Phase I clinical trial material.

Group B Streptococcal Vaccine

A cost effective, novel Group B Streptococcus (GBS) hexavalent conjugate vaccine candidate for maternal immunization.

Nearly 20 percent of women worldwide carry the GBS bacterium, which can live in the gastrointestinal tract and the vagina and be passed from mother to baby in the womb or during birth that can cause infection. Usually GBS is not serious for adults, but it can hurt newborns. GBS is a leading cause of stillbirth worldwide. In the United States, GBS bacteria are a leading cause of meningitis and bloodstream infections in a newborn’s first three months of life. Currently a vaccine to prevent GBS is not available. 

Hexavalent conjugated vaccine candidate which leverages Inventprise’s (Hz-PEG-Hz) peg linker platform technology

Preclinical optimization and supported by a vaccine development grant from the Bill and Melinda Gates Foundation.

Quadrivalent meningococcal vaccine

A cost effective, novel, quadrivalent meningococcal vaccine candidate

The meningococcal market is diverse and complex with regional variations in serogroup distribution and significant use outside of routine immunization. Discontinued production of polysaccharide vaccines has reduced domestic access. The available supply of conjugate MenACWY is insufficient to meet demand growth triggered by rising incidence of serogroups C and W and reduced availability of polysaccharide vaccines. Low-middle income countries  and the Global Stockpile struggle for access to multivalent and conjugate vaccines due to limited global access to supply for polysaccharide vaccines and high cost for conjugate vaccines.

Quadrivalent conjugated vaccine candidate leverages our proprietary (Hz-PEG-Hz) peg linker platform technology

Self-funded the Neisseria meningococcal conjugate vaccine-4 program continues to advance through development, and it is anticipated to reach preclinical optimization by 2022.

Hemophilus Influenza A candidate

A novel conjugate vaccine candidate indicated to prevent Hia, a rare but deadly infection primarily affecting the native peoples of North America.

Hemophilus Influenza A was recognized as an important pathogen causing severe infections in young children with a high case-fatality rate. Remarkably, the highest incidence rates of invasive Hia disease are found in North American Indigenous populations, specifically Indigenous tribes  of  Navajo and Inuit. In these populations Hia has become the leading cause of bacterial meningitis among children.

Monovalent conjugated vaccine candidate leveraging proprietary (Hz-PEG-Hz) peg linker platform technology

Preclinical optimization and supported by a vaccine development grant from the Bill and Melinda Gates Foundation.

Yellow Fever Vaccine Candidate

Experimental vaccine candidate in urgent development to address global supply shortages

Yellow fever reemergence throughout Africa and the Americas has put 900 million people in 47 countries at risk of contracting the disease. Although the existing vaccine has been an important tool to controlling yellow fever epidemics, its egg-based live-attenuated nature comes with a range of contraindications that prompts advising against its administration to pregnant and lactating women, immunocompromised individuals, and those with hypersensitivity to chicken egg proteins. Additionally, large outbreaks have highlighted problems with insufficient vaccine supply, whereby manufacturers rely on slow traditional manufacturing processes that prevent them from ramping up production. These limitations have contributed to an inadequate control of yellow fever and have favored the pursuit of novel yellow fever vaccine candidates that aim to circumvent the licensed vaccine’s restrictions.

IVT has produced GMP Vero cell banks from WHO for manufacturing purposes and have selected the best candidates as viral seed materials for a Vero cell produced YF Vaccine.

Shigella Vaccine Candidate

Shigellosis is an important cause of morbidity and mortality among pre-school-aged children, older children and adults in Sub-Saharan Africa and South Asia. It has been identified as a major cause of moderate to severe diarrhea. The percentage resistance to shigella is increasing rapidly with no vaccine currently available to prevent the tens of millions of infections per year.. A vaccine against Shigellosis is urgently required to be developed

4-valent conjugate vaccine of native or short chain O-antigen of Four Shigella strains conjugated in sun-type array to Shigella Ipa B/C protein as carrier.

Shigella serotypes (namely 3 New Shigella serotypes isolates /Univ of Maryland ( sonnei, S. flexneri 3a and Shigella boydii 6) will be evaluated during the current grant. A 4-valent conjugate vaccine will be manufactured and tested for animal immunogenicity

.

IVT-Human Papillomavirus-09

Human papillomavirus infection (HPV infection) is an infection caused by human papillomavirus (HPV), a DNA virus from the Papillomaviridae family, Many HPV infections cause no symptoms, and 90% resolve within two years, however in some cases, an HPV infection persists and results in either warts or precancerous lesions. These lesions, depending on the site affected, increase the risk of cancer of the cervix, vulva, vagina, penis anus, mouth, tonsils, or throat. Nearly all cervical cancer is due to HPV; two strains, HPV16 and HPV18, account for 70% of cases. HPV16 is responsible for almost 90% of HPV positive, oropharyngeal cancers. Between 60% and 90% of the other cancers listed above are also linked to HPV.[HPV is the most common sexually transmitted infection (STI) globally. Worldwide an estimated 569,000 new cases of cervical cancer occurred, with 311,000 deaths. Around 85% of these cervical cancers occurred in low and middle-income countries. In the United States, about 30,700 cases of cancer due to HPV occur each year.

Vaccine plafform comprising VLPs ( virus like particles ) that encap sulate an immunogenic component and a stabilizing agent.

Pre-clinical optimization, self funded. Discussions with potential collaborators ongoing.

Mirconeedle Patch

Dissolvable Micro-needle patch designed for low resource settings. Candidate has the ability to include multiple antigens on one patch.

Microarray patches (MAPs), also referred to as microneedle patches, are a novel methodology that have the potential to overcome barriers to vaccine delivery in low and middle-income countries (LMIC).

Inventprise is developing a novel MAP technology with the potential to tackle vaccine delivery challenges facing current vaccine presentations and storage.

Inventprise is developing medical-silicone grade molds which are sterilizable, reusable and currently exploring three types of molds with varying height and base in order to establish a microneedle with the appropriate TPP

Keep In Touch

Facebook-f Linkedin-in

Phone : (+1) 206-258-2660

Business Enquiries : business@inventprise.com

General Contact: info@inventprise.com

Inventprise locations

Facility 1 - Viral R&D / Manufacturing

Facility 3 - Small-scale cGMP Manufacturing

Facility 2 - Bacterial R&D

Facility 4 - Large-scale Manufacturing

© 2012 – 2022 Inventprise – All Rights Reserved.